Jean-Louis Pujol

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Fabrice Barlési, Julien Mazières, Jean‐Philippe Merlio et al. · The Lancet · 2016 · 984 citations

Medicine, Molecular Medicine, Oncology +11

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Perioperative Nivolumab in Resectable Lung Cancer

Tina Cascone, Mark M. Awad, Jonathan Spicer et al. · New England Journal of Medicine · 2024 · 447 citations · Full text

Medicine, Oncology, Surgery +17

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

John R. Eckardt, Joachim von Pawel, Jean-Louis Pujol et al. · Journal of Clinical Oncology · 2007 · 384 citations

Medicine, Oncology, Pharmacology +13

Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer

Jean-Louis Pujol, Jean‐Christophe Grenier, J.-P. Daurès et al. · Lung Cancer · 1993 · 320 citations

Medicine, Cell Biology, Oncology +8